Cidara Therapeutics, Inc. (CDTX) Stock

About Cidara Therapeutics, Inc.

Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.

Cidara Therapeutics, Inc. is headquartered in US.

Cidara Therapeutics, Inc. (CDTX) stock trades at $221.38 with a market capitalization of $5.61B. The stock is valued at a negative price-to-earnings (P/E) ratio of -25.99, reflecting a net loss over the last twelve months, price-to-book of 8.15, price-to-sales of 5613.78. Over the past 52 weeks the stock has ranged between $15.22 and $221.42, and currently trades at or near its 52-week high.

On profitability, Cidara Therapeutics, Inc. generates a return on equity (ROE) of -37.30% (negative, reflecting a net loss), return on capital employed of -33.41%, an operating margin of -17600.00%, a net profit margin of -17000.00%.

Official website: www.cidara.com

Cidara Therapeutics, Inc. by the numbers, 2015–2024

Between 2015 and 2024 Cidara Therapeutics, Inc. reported revenue of $0 rising to $1.0M. Compounded, revenue has grown -45.6% a year over five years, -72.9% over three, -95.7% over the last twelve months. Net profit fell to $-170.0M.

The most recent net margin is -17000.00%. On a trailing twelve-month basis to Sep '25, revenue is $0 and net profit $-184.0M.

Borrowings stand at $4.0M, cash on hand is $293.7M, cash from operations was $-177.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -83.9% over five years, and was -104.3% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Cidara Therapeutics, Inc. (CDTX) — frequently asked questions